Exkivity: Withdrawal of the marketing authorisation application



Takeda Pharma A/S withdrew its application for a conditional marketing authorisation of Exkivity (mobocertinib) for the treatment of a certain type of lung cancer.

The company withdrew the application on 20 July 2022.

Key facts

Product number
International non-proprietary name (INN) or common name
  • mobocertinib
Active substance
  • mobocertinib
Date of withdrawal
Company making the application
Takeda Pharma A/S
Withdrawal type
Initial authorisation

Related information on withdrawals

A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.

An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').

How useful was this page?

Add your rating